merislon eisai tokyo japan 相關
廣告
搜尋結果
2024年4月11日 · April 8, 2024. Eisai Participates in Kakamigahara City’s SDGs Promotion Program through its Activities Including Waste Recycling at the Kawashima Plant. October 13, 2023. Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness. March 9, 2023.
2022年11月7日 · TOKYO, Nov 7, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon
Betahistine mesilate (a derivative of Betahistine) is reported as an ingredient of Merislon in the following countries: China. Costa Rica. Dominican Republic. El Salvador. Guatemala. Hong Kong. Indonesia. Japan.
2022年7月11日 · 07-11-2022 Print. Japanese drug major Eisai (TYO: 4523) today announced that it has entered into an agreement to divest its rights for muscle relaxant Myonal (eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon (betahistine mesilate) in Asia to a subsidiary of Switzerland-based DKSH Holding Ltd.
天主教耕莘醫療財團法人耕莘醫院 電話：耕莘醫院(02)22193391 / 安康院區(02)22123066 / 預約掛號：(02)22195028 耕莘醫院地址：23148新北市新店區中正路362號 / 安康院區地址：23155新北市新店區車子路15號 / Email：service@cth.org.tw
由於此網站的設置，我們無法提供該頁面的具體描述。
Merislon 6 MG Tablet is used for the treatment of vertigo associated with the Meniere’s disease (disorder of your inner ear). The medicine decreases the pressure in your ears, which is supposedly the reason for the sense of nausea, dizziness and vertigo related to the disease. and vertigo related to the disease.
